2022 World Conference on Lung Cancer (ePosters)-EP08.01-052. Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study

Pdf Summary

The combination of toripalimab, an immune checkpoint inhibitor, with cytokine induced killer (CIK) cells is being explored as a potential treatment option for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 expression. Previous studies have shown that combining PD-1 monoclonal antibody with CIK cells can have positive clinical effects in the treatment of metastatic renal cell carcinoma. This single-center exploratory study aims to evaluate the safety and efficacy of toripalimab in combination with CIK cells in NSCLC.<br /><br />The study enrolled newly-diagnosed advanced NSCLC patients with positive PD-L1 expression. The patients were divided into three groups: toripalimab plus CIK cells, toripalimab plus CIK cells and chemotherapy, and CIK cells plus chemotherapy. The primary endpoint of the study is safety and progression-free survival (PFS), with secondary endpoints including overall response rate (ORR), disease control rate (DCR), and overall survival (OS). The study also aims to evaluate biomarkers and the role of PD-L1, TMB, and TCR in the combination therapy.<br /><br />So far, 25 patients have been enrolled in the study. In the intention-to-treat population, 60% of patients in the toripalimab plus CIK cells group achieved a partial response (PR), while 20% had stable disease (SD). In the toripalimab plus CIK cells and chemotherapy group, 33.33% of patients achieved a partial response (PR), and 55.56% had stable disease (SD). The control group has enrolled one patient so far.<br /><br />The combination therapy has shown promising clinical activity in patients with positive PD-L1 expression, but further analyses and evaluation of biomarkers are still ongoing. The study is expected to continue enrolling patients until January 2023. The authors express their gratitude to the patients participating in the trial and their families, and the study is supported by Shanghai Junshi Bioscience Co. LTD. There are no conflicts of interest declared by the authors.

Asset Subtitle

Xuxinyi Ling

Meta Tag

Speaker Xuxinyi Ling

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

toripalimab

immune checkpoint inhibitor

cytokine induced killer cells

non-small cell lung cancer

PD-L1 expression

biomarkers

combination therapy

progression-free survival

clinical activity

patient enrollment